Page Title
Drug Development Pipeline
KB407
Status
Phase OneTherapeutic Approach
Genetic Therapy
KB407 is an experimental inhaled gene therapy for CF. It uses a viral vector, a type of delivery vehicle for genetic therapies, to deliver a functional copy of the CFTR gene into the lung cells of people with CF. This would allow the lung cells to make normally functioning CFTR protein, regardless of an individual’s specific CFTR mutation.
Status
A Phase 1 study to test the safety and tolerability of KB407 in adults with CF is currently underway.
Sponsor
This program is sponsored by Krystal Biotech. It is being conducted within the Therapeutics Development Network.

CONTACT THE CLINICAL TRIAL NAVIGATOR
Get personalized assistance and answers to your clinical trial questions.
Learn MoreSign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.
Learn More